Q&A

Why is Hospira Healthcare moving to a non-DEHP product portfolio?

To date there have been no known cases of toxicity or adverse events directly attributed to DEHP content; nevertheless, Health Canada recommends precautions that include limiting medical exposure to DEHP in potentially at-risk patient groups, such as male newborns, infants and young children, pregnant women carrying a male fetus, and peripubertal males.¹

¹ Health Canada draft position statement on DEHP. Accessed March 19, 2010 at www.hc-sc.gc.ca

How will this transition affect me?

How will the upgrade to non-DEHP products affect my contract prices?

What will be the difference between the sets I am currently using and non-DEHP sets?

Will case unit of measure or other dimensions of these products change?

Will non-DEHP information appear on the label – will it be easy to distinguish between the old (DEHP) and new product lines?

When should my facility expect the transition from DEHP products to non-DEHP will begin?

All products included in this fourth wave of implementation will be available from Hospira starting December 7, 2011. It will not be possible to purchase the new non-DEHP products before that date, nor will it be possible to order the equivalent DEHP product from Hospira after that date. A complete list of products involved in this phase of the Non-DEHP Transition is available now at www.nonDEHP.ca.

By what date will the entire portfolio transition be completed?

Following this fourth wave of the transition, 95% of Hospira gravity and pump administration sets portfolio will be Non-DEHP. We expect to convert the remaining 5% of Hospira IV gravity and pump administration sets in 2012. Hospira will communicate with our valued customers in a timely fashion prior to the next phase of the transition.

Can I return the DEHP products I have in stock?

In anticipation of this transition, we kindly request that your staff ensures depletion of your DEHP products still in stock as per your current inventory management practices, as Hospira would be unable to accept returns of DEHP inventory due to overstock at your facilities.

For more information about Hospira policies regarding ineligible, unused or overstock products, please refer to our returned goods policy document available online at www.hospira.ca.

Will non-DEHP IV administration sets have other differences from the products we currently use?

Why is Hospira discontinuing some of the current products during this transition to non-DEHP?

Hospira Canada is an established leader in the Canadian IV therapy marketplace, offering a wide range of products to suit our customers’ diverse needs. As clinical practice evolves, the demand for some products has diminished significantly. Hospira’s focus will always be on manufacturing quality products that meet the needs of our customers.

When will the next wave of the Non-DEHP Transition begin?

Hospira is currently analyzing manufacturing capacity to determine an appropriate start date for the next phase of this transition. Hospira will communicate with our valued customers in a timely fashion prior to each phase of the transition.

To view Hospira’s Non-DEHP Transition Guide click here. Our team of dedicated Hospira sales representatives, as well as our Clinical Support and Customer Service staff, remains at your disposal for any questions or concerns you may have.